Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) EBT (2016 - 2025)

Historic EBT for Pharma-Bio Serv (PBSV) over the last 16 years, with Q4 2025 value amounting to $4254.0.

  • Pharma-Bio Serv's EBT rose 12864.84% to $4254.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$94260.0, marking a year-over-year increase of 8752.26%. This contributed to the annual value of -$94260.0 for FY2025, which is 8752.26% up from last year.
  • According to the latest figures from Q4 2025, Pharma-Bio Serv's EBT is $4254.0, which was up 12864.84% from -$209029.0 recorded in Q3 2025.
  • In the past 5 years, Pharma-Bio Serv's EBT registered a high of $2.3 million during Q3 2021, and its lowest value of -$4.8 million during Q4 2021.
  • In the last 5 years, Pharma-Bio Serv's EBT had a median value of $165954.0 in 2022 and averaged $7507.4.
  • Within the past 5 years, the most significant YoY rise in Pharma-Bio Serv's EBT was 19414.01% (2021), while the steepest drop was 324841.92% (2021).
  • Over the past 5 years, Pharma-Bio Serv's EBT (Quarter) stood at -$4.8 million in 2021, then skyrocketed by 104.82% to $231044.0 in 2022, then plummeted by 120.7% to -$47835.0 in 2023, then soared by 68.96% to -$14849.0 in 2024, then surged by 128.65% to $4254.0 in 2025.
  • Its EBT was $4254.0 in Q4 2025, compared to -$209029.0 in Q3 2025 and $100864.0 in Q2 2025.